Chart Review of Patients Undergoing Ketamine Treatments for Depression

NCT ID: NCT07099235

Last Updated: 2025-08-01

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 250 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-04-01
• Study Completion Date: 2025-06-29

Brief Summary

The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression. This retrospective, observational study aims to conduct a chart review on patients receiving ketamine in a naturalistic setting to develop our understanding of ketamine as an interventional approach for treatment-resistant depression.

Conditions

Depression - Major Depressive Disorder

Study Design

• Observational Model Type: ECOLOGIC_OR_COMMUNITY
• Study Time Perspective: RETROSPECTIVE

Study Groups

Treatment-resistant Major Depressive Disorder (MDD); DSM-5 Diagnosis of MDD

ketamine hydrochloride

Intervention Type: DRUG

Racemic ketamine is a 50/50 mixture of enantiomers (S)-ketamine and (R)-ketamine. The repeated administration of racemic ketamine intravenously at subanesthetic doses has emerged as an efficacious treatment for treatment-resistant depression.

Interventions

ketamine hydrochloride

Racemic ketamine is a 50/50 mixture of enantiomers (S)-ketamine and (R)-ketamine. The repeated administration of racemic ketamine intravenously at subanesthetic doses has emerged as an efficacious treatment for treatment-resistant depression.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18
• Able to provide informed consent
• Patient diagnosed with treatment-resistant depression
• Outpatient recommended and approved by psychiatrist for ketamine treatment
• Individuals who have previously received ECT, rTMS or any other neuromodulation can also receive ketamine

Exclusion Criteria

• History of psychosis/comorbid psychiatric disorders/psychotic depression/dissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist
• Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment
• History of substance misuse and/or dependence, including chronic alcohol abuse
• Previous ketamine use
• Acute dementia/delirium
• Pregnancy/breastfeeding
• Previous sensitivity to ketamine or related compounds
• Unstable medical condition which may require anesthesia consult
• History of elevated intracranial pressure or cerebrovascular accident
• Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sunnybrook Health Sciences Centre

OTHER

Sponsor Role: lead

Responsible Party

Dr. Fahad Alam

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Ontario Ketamine and Infusion Centre - Toronto Site

Mississauga, Ontario, Canada

Countries

Canada

Other Identifiers

6828

Identifier Type: -

Identifier Source: org_study_id